What excitotoxin kills striatal neurons in huntington’s disease? Clues from neurochemical studies

Neurology

Volumn 40, Issue 1, 1990, Pages 20-24

  Perry, Thomas L ^a   Hansen, Shirley ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; GLYCINE;

ADULT; ARTICLE; AUTOPSY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CORPUS STRIATUM; HUMAN; HUNTINGTON CHOREA; PRIORITY JOURNAL;

ADULT; AMINO ACIDS; CAUDATE NUCLEUS; GLUTAMATES; GLUTAMIC ACID; HUMAN; HUNTINGTON DISEASE; MIDDLE AGE; NEUROTOXINS; PUTAMEN; SUPPORT, NON-U.S. GOV'T;

EID: 0025096709     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.40.1.20     Document Type: Article

References (31)

1. Schwarcz R, Shoulson I. Excitotoxins and Huntington’s disease. In: Coyle JT, ed. Animal models of dementia. New York: Alan R Liss, 1987:39–68.
2. Beal MF, Mazurek MF, Ellison DW, et al. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington’s disease. Ann Neurol 1988;23:562–569.
3. Young AB, Greenamyre JT, Hollingsworth Z, et al. NMDA receptor losses in putamen from patients with Huntington’s disease. Science 1988;241:981–983.
4. Olney JW. Glutamate-induced retinal degeneration in neonatal mice. Electron microscopy of the acutely evolving lesion, J Neuro-pathol Exp Neurol 1969;28:455–474.
5. Olney JW, De Gubareff T. Glutamate neurotoxicity and Huntington’s chorea. Nature 1978;271:557–559.
6. Schwarcz R, Whetsell WO, Mangano RM. Quinolinic acid an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983;219:316–318.
7. Reynolds GP, Pearson SJ, Halket J, Sander M. Brain quinolinic acid in Huntington’s disease. J Neurochem 1988;50:1959–1960.
8. Schwarcz R, Tamminga CA, Kurlan R, Shoulson I. Cerebrospinal fluid levels of quinolinic acid in Huntington’s disease and schizophrenia. Ann Neurol 1988;24:580–582.
9. Nadler JV, Wang A, Hakim A. Toxicity of L-proline toward rat hippocampal neurons. Brain Res 1988;456:168–172.
10. Rieke GK, Scarfe AD, Hunter JF. L-Pyroglutamate: an alternate neurototoxin for a rodent model of Huntington’s disease. Brain Res Bull 1984;13:443–456.
11. Lehmann J, Tsai C, Wood PL. Homocysteic acid as a putative excitatory amino acid neurotransmitter: I. Postsynaptic characteristics at N-methyl-D-aspartate-type receptors on striatal cho-linergic interneurons. J Neurochem 1988;51:1765–1770.
12. Turski WA. Homocysteic acid convulsant action of stereoisomers in mice. Brain Res 1989;479:371–373.
13. 3H]MK-801 binding to the NMDA receptor in rat brain. Eur J Pharmacol 1987; 142:487–488.
14. Perry TL, Hansen S, Gandham SS. Postmortem changes of amino compounds in human and rat brain. J Neurochem 1981;36:406–412.
15. Perry TL, Hansen S, Jones K. Brain glutamate deficiency in amyotrophic lateral sclerosis. Neurology 1987;37:1845–1848.
16. Perry TL. Four biochemically different types of dominantly inherited olivopontocerebellar atrophy. In: Duvoisin RC, Plaitakis A, eds. The olivopontocerebellar atrophies. New York Raven Press, 1984:205–216.
17. Perry TL, Berry K, Hansen S, Diamond S, Mok C. Regional distribution of amino acids in human brain obtained at autopsy. J Neurochem 1971;18:513–519.
18. Perry TL, Kish SJ, Hansen S, Currier RD. Neurotransmitter amino acids in dominantly inherited cerebellar disorders. Neurology 1981;31:237–242.
19. Perry TL, Stedman D, Hansen S. A versatile lithium buffer elu-tion system for single column amino acid chromatography. J Chromatogr 1968;38:460–466.
20. Perry TL, Hansen S, Kennedy J. CSF amino acids and plasma-CSF amino acid ratios in adults. J Neurochem 1975;24:587–589.
21. Perry TL, Hansen S, Wall RA, Gauthier SG. Human CSF GABA concentrations: revised downward for controls, but not decreased in Huntington’s chorea. J Neurochem 1982;38:766–773.
22. Perry TL, Hansen S, Kloster M. Huntington’s chorea: Deficiency of γ-aminobutyric acid in brain. N Engl J Med 1973;288:337–342.
23. Reynolds GP, Pearson SJ. Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington’s disease brain. Neurosci Lett 1987;78:233–238.
24. Ellison DW, Beal MF, Mazurek MF, Malloy JR, Bird ED, Martin JB. Amino acid neurotransmitter abnormalities in Huntington’s disease and the quinolinic acid animal model of Huntington’s disease. Brain 1987;110:1657–1673.
25. Cross AJ, Slater P, Reynolds GP. Reduced high affinity glutamate uptake sites in the brains of patients with Huntington’s disease. Neurosci Lett 1986;67:198–202.
26. Marstein S, Jellum E, Halpern B, Eldjarn L, Perry TL. Biochemical studies of erythrocytes in a patient with pyroglutamic acidemia (5-oxoprolinemia). N Engl J Med 1976;295:406–412.
27. Marstein S, Jellum E, Nesbakken R, Perry TL. Biochemical investigations of biopsied brain tissue and autopsied organs from a patient with pyroglutamic acidemia (5-oxoprolinemia). Clin Chim Acta 1981;111:219–228.
28. Miyamoto M, Murphy TH, Schnarr RL, Coyle JT. Antioxidants protect against glutamate cytotoxicity in a neuronal cell line. SOC Neurosci Abstr 1988;14:420.
29. Perry TL, Yong VW, Hansen S, et al. Tissue culture evidence for a circulating neurotoxin in Huntington’s chorea. J Neurol Sci 1987;78:139–150.
30. Wong EHF, Kemp JA, Priestly T, Knight AR, Woodruff GN, Iversen LL. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 1986;83:7104–7108.
31. Foster AC, Gill R, Woodruff GN. Neuroprotective effects of MK-801 in uiuo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. J Neurosci 1988;8:4745–4754.